Lunai Bioworks Inc. has announced its intention to voluntarily delist its common stock from Nasdaq following a determination from the exchange regarding its financial condition. This decision is significant as it highlights the ongoing challenges faced by the company and reflects broader issues within the pharmaceutical preparations industry.
On October 21, 2026, Lunai Bioworks received a letter from Nasdaq's Listing Qualifications Department stating that the company no longer meets the minimum stockholders' equity requirement of $2,500,000, as outlined in Nasdaq Listing Rule 5550(b)(1). The company reported a stockholders' deficit of $(9,024,946) in its recent Annual Report for the fiscal year ending June 30, 2026. Furthermore, Lunai Bioworks does not qualify for alternative continued listing standards based on market value or net income.
In light of this determination, Lunai's Board of Directors approved the voluntary withdrawal of its common stock from listing on Nasdaq on October 22, 2026. The Board concluded that the costs associated with continued listing and SEC reporting were not justified given the company's financial situation. Trading in Lunai's common stock is expected to be suspended at the opening of business on October 30, 2026, unless the company requests a hearing, which it does not intend to do.
The company plans to file a Form 25 with the SEC around November 2, 2026, to officially withdraw its common stock from listing, with the delisting expected to become effective approximately ten days later. Following the delisting, Lunai intends to file a Form 15 to suspend its reporting obligations under the Exchange Act, provided it is eligible.
The filing also noted that Lunai does not plan to seek quotation of its common stock on any over-the-counter market, raising concerns about the future trading of its shares. The company cannot guarantee that any broker-dealer will quote its stock or that any trading market will exist after the Nasdaq suspension.
In addition to the delisting news, the filing disclosed that Nathen Fuentes resigned as Chief Financial Officer on the same day, with no immediate successor appointed. Douglas W. Calder also resigned from the Board, affecting the composition of the Audit and Compensation Committees, which no longer meet Nasdaq's requirements for membership.
This situation may have ripple effects across the pharmaceutical preparations industry, as Lunai's exit from Nasdaq could provide opportunities for competitors. As the company navigates these challenges, it remains to be seen how it will manage its financial and operational strategies moving forward.
Details were not available in the SEC filing regarding any immediate next steps beyond the planned filings.